

Biomed 2025 Abstract – CorNeat Vision

Company name: CorNeat Vision Ltd.

Website: www.corneat.com

CEO name: Almog Aley-Raz

CATEGORY: Medical Devices

SESSIONS:

- Illuminating the Path; Innovations and Challenges in Eye Care

- Executive Summary / Investment Rational

CorNeat Vision's flagship product, the CorNeat KPro, is an artificial cornea that enables corneally blind patients to fully rehabilitate their vision without the need for donor tissue. The CorNeat KPro solution addresses the acute global shortage of donor tissue while providing superior and stable optical performance, as well as an aesthetic appearance that are poised to displace the use of tissue as the standard of care. The CorNeat KPro is currently in its second clinical trial, designed to meet FDA, CE Mark, and NMPA requirements. Interim results, which will be presented, demonstrate the dramatic impact of the device on patients' lives. The company, which is also developing solutions for other blinding conditions related to glaucoma and sclera, has already raised \$20M, as well as \$7.5M from the EIC, US Army, and US Navy.

- Core Technology

CorNeat Vision products leverage a novel, non-degradable, tissue-integrating material technology. This technology, EverMatrix, enables the permanent integration of synthetic materials with living tissue, reinforcing soft and bone tissue, and avoiding the foreign body response around implants.

- Product Profile/Pipeline

CorNeat Vision product portfolio includes the EverPatch+, a synthetic nondegradable scleral reinforcement matrix, which is FDA cleared, the eShunt, a long-lasting minimally invasive device that address severe glaucoma, and the CorNeat KPro.

- Business Strategy

CorNeat Vision sells directly to end customer in the US leveraging a fully owned distribution subsidiary that, at present, leverages 20 independent sales reps. The company's implants are manufactured in its cleanroom facility in Israel, ensuring rigorous quality control and efficient supply chain management. The

approval of the company's 1st product, EverPatch+, enables it to generate early revenues while establishing a presence in the US market and expand its global distribution ahead of its flagship products.

- What's Next?

CorNeat Vision plans to complete clinical evaluations and commercialize its 3 ophthalmic implants within the next 2 years and expand their use globally, growing a substantial global business. It also plans to expand the use of its core technology to additional field by leveraging partnerships, co-development, and licensing models.